Primary prevention and coronary heart disease: the economic benefits of lowering serum cholesterol
- PMID: 3486601
- PMCID: PMC1646773
- DOI: 10.2105/ajph.76.6.647
Primary prevention and coronary heart disease: the economic benefits of lowering serum cholesterol
Abstract
We examined the expected economic benefits of cholesterol lowering for adult men with significant elevations of total serum cholesterol (above 260 mg/dl), incorporating estimates of direct benefits from anticipated reductions in lifetime expenditures for medical care, and estimates of indirect benefits related to extension of work-life secondary to reductions in morbidity and premature mortality. Our findings yield discounted lifetime direct benefits of a 15 per cent reduction in total serum cholesterol of $3 to $208 per person, and discounted lifetime indirect benefits of $1 to $8,946. Benefits increase with an individual's initial cholesterol level and decrease with the age at which an intervention is initiated. Economic benefits increase approximately twofold in the presence of other coronary risk factors, such as cigarette smoking and hypertension. Results suggest that cholesterol-lowering interventions, no matter what their cost, are unlikely to result in substantial direct savings to the health care system. However, the indirect benefits of intervention are quite high for young and middle-aged adults, as well as for those with severe elevations of cholesterol or with additional coronary risk factors.
Similar articles
-
Serum cholesterol and long-term prognosis in middle-aged men with myocardial infarction and angina pectoris. A 16-year follow-up of the Primary Prevention Study in Göteborg, Sweden.Eur Heart J. 1997 May;18(5):754-61. doi: 10.1093/oxfordjournals.eurheartj.a015340. Eur Heart J. 1997. PMID: 9152645
-
ESC Population Studies Lecture 1996. Cardiovascular monitoring of a city over 30 years.Eur Heart J. 1997 Aug;18(8):1220-30. doi: 10.1093/oxfordjournals.eurheartj.a015433. Eur Heart J. 1997. PMID: 9458414
-
An economic evaluation of lovastatin for cholesterol lowering and coronary artery disease reduction.Am J Cardiol. 1991 Apr 15;67(9):789-96. doi: 10.1016/0002-9149(91)90609-o. Am J Cardiol. 1991. PMID: 1901436
-
[Therapy and prevention of coronary heart diseases through lowering of the serum cholesterol levels; third consensus 'Cholesterol'. Consensus Working Group, CBO].Ned Tijdschr Geneeskd. 1998 Sep 19;142(38):2096-101. Ned Tijdschr Geneeskd. 1998. PMID: 9856223 Review. Dutch.
-
[Trials of primary prevention by diet or hypolipidemic treatment].Arch Mal Coeur Vaiss. 1992 Sep;85 Spec No 2:97-103. Arch Mal Coeur Vaiss. 1992. PMID: 1285703 Review. French.
Cited by
-
A cost-effectiveness analysis of exercise as a health promotion activity.Am J Public Health. 1988 Nov;78(11):1417-21. doi: 10.2105/ajph.78.11.1417. Am J Public Health. 1988. PMID: 3140681 Free PMC article.
-
Lifetime health and economic benefits of weight loss among obese persons.Am J Public Health. 1999 Oct;89(10):1536-42. doi: 10.2105/ajph.89.10.1536. Am J Public Health. 1999. PMID: 10511836 Free PMC article.
-
Cost-effectiveness analysis of treatments to reduce cholesterol levels, blood pressure and smoking for the prevention of coronary heart disease: evaluative study carried out in Spain.Pharmacoeconomics. 1998 May;13(5 Pt 2):623-43. doi: 10.2165/00019053-199813050-00014. Pharmacoeconomics. 1998. PMID: 17165328
-
Cost effectiveness of adding ezetimibe to atorvastatin therapy in patients not at cholesterol treatment goal in Canada.Pharmacoeconomics. 2006;24(8):815-30. doi: 10.2165/00019053-200624080-00007. Pharmacoeconomics. 2006. PMID: 16898850
-
One state's approach to the regulation of cholesterol screening.Public Health Rep. 1990 Nov-Dec;105(6):584-8. Public Health Rep. 1990. PMID: 2124359 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical